Kevin F.  McLaughlin net worth and biography

Kevin McLaughlin Biography and Net Worth

Mr. McLaughlin joined Acceleron in November 2010 and is the Senior Vice President, Chief Financial Officer and Treasurer. He most recently served as Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company. He was a co-founder of Aptius Education, Inc. and from 2007 through 2009 he worked as the Chief Operating Officer and a director. From 1996 through 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc. He joined PRAECIS as their first Chief Financial Officer where he had responsibility for private financings, partnership financings, the company’s initial public offering and subsequent stock offering. Later, Mr. McLaughlin became COO, and then President and CEO, and he served as a member of the Board of Directors. In this capacity he was responsible for negotiating the sale of the company to GlaxoSmithKline. Since January 2015, Mr. McLaughlin has served on the Board of Directors of Vericel Corporation, and since August 2017 has served on the Board of Directors of Stealth Biotherapeutics Inc. He began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin received a B.S. in business from Northeastern University and an M.B.A. from Babson College.

What is Kevin F. McLaughlin's net worth?

The estimated net worth of Kevin F. McLaughlin is at least $1.89 million as of January 4th, 2021. Mr. McLaughlin owns 10,592 shares of Acceleron Pharma stock worth more than $1,893,320 as of November 19th. This net worth estimate does not reflect any other investments that Mr. McLaughlin may own. Learn More about Kevin F. McLaughlin's net worth.

How do I contact Kevin F. McLaughlin?

The corporate mailing address for Mr. McLaughlin and other Acceleron Pharma executives is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. Acceleron Pharma can also be reached via phone at (617) 649-9200 and via email at [email protected]. Learn More on Kevin F. McLaughlin's contact information.

Has Kevin F. McLaughlin been buying or selling shares of Acceleron Pharma?

Kevin F. McLaughlin has not been actively trading shares of Acceleron Pharma during the past quarter. Most recently, Kevin F. Mclaughlin sold 19,630 shares of the business's stock in a transaction on Thursday, September 23rd. The shares were sold at an average price of $160.31, for a transaction totalling $3,146,885.30. Learn More on Kevin F. McLaughlin's trading history.

Who are Acceleron Pharma's active insiders?

Acceleron Pharma's insider roster includes Habib Dable (CEO), Sujay Kango (EVP), Terrence Kearney (Director), Thomas McCourt (Director), Kevin McLaughlin (CFO), Adam Veness (SVP), and Joseph Zakrzewski (Director). Learn More on Acceleron Pharma's active insiders.

Kevin F. McLaughlin Insider Trading History at Acceleron Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/23/2021Sell19,630$160.31$3,146,885.30View SEC Filing Icon  
1/4/2021Sell3,280$124.08$406,982.4010,592View SEC Filing Icon  
12/14/2020Sell42,528$130.14$5,534,593.9218,468View SEC Filing Icon  
12/10/2020Sell500$125.12$62,560.0011,764View SEC Filing Icon  
4/8/2020Sell36,774$85.51$3,144,544.7415,216View SEC Filing Icon  
1/2/2020Sell5,579$52.50$292,897.508,713View SEC Filing Icon  
12/13/2019Sell11,853$50.28$595,968.8410,426View SEC Filing Icon  
9/10/2019Sell8,000$45.30$362,400.0022,452View SEC Filing Icon  
4/9/2019Sell12,000$44.62$535,440.0030,379View SEC Filing Icon  
4/2/2019Sell648$48.02$31,116.9642,279View SEC Filing Icon  
1/2/2019Sell5,712$42.80$244,473.6042,527View SEC Filing Icon  
8/30/2018Sell12,500$54.00$675,000.0056,439View SEC Filing Icon  
6/29/2018Sell25,000$48.00$1,200,000.0068,939View SEC Filing Icon  
4/3/2018Sell4,000$38.45$153,800.00View SEC Filing Icon  
1/4/2018Sell19,000$42.89$814,910.0045,300View SEC Filing Icon  
1/2/2018Sell4,000$42.42$169,680.0045,300View SEC Filing Icon  
9/12/2017Sell16,000$38.41$614,560.0050,810View SEC Filing Icon  
7/5/2017Sell34,400$32.00$1,100,800.0080,950View SEC Filing Icon  
1/4/2017Sell1,700$27.45$46,665.0072,200View SEC Filing Icon  
7/1/2016Sell25,300$34.66$876,898.0082,900View SEC Filing Icon  
10/7/2015Sell7,000$24.38$170,660.0080,000View SEC Filing Icon  
9/8/2015Sell6,500$30.16$196,040.0040,000View SEC Filing Icon  
7/7/2015Sell7,000$29.70$207,900.00View SEC Filing Icon  
6/8/2015Sell6,500$32.49$211,185.00View SEC Filing Icon  
4/7/2015Sell7,000$34.88$244,160.00View SEC Filing Icon  
3/9/2015Sell6,500$40.25$261,625.00View SEC Filing Icon  
1/12/2015Sell2,000$40.66$81,320.00View SEC Filing Icon  
1/7/2015Sell5,000$39.46$197,300.00View SEC Filing Icon  
12/8/2014Sell10,000$44.02$440,200.00View SEC Filing Icon  
10/7/2014Sell10,000$29.25$292,500.00View SEC Filing Icon  
9/9/2014Sell10,000$24.48$244,800.00View SEC Filing Icon  
9/8/2014Sell3,300$24.90$82,170.00View SEC Filing Icon  
8/14/2014Sell10,000$29.78$297,800.00View SEC Filing Icon  
7/7/2014Sell10,000$31.72$317,200.00View SEC Filing Icon  
6/9/2014Sell10,000$31.65$316,500.00View SEC Filing Icon  
See Full Table

Kevin F. McLaughlin Buying and Selling Activity at Acceleron Pharma

This chart shows Kevin F Mclaughlin's buying and selling at Acceleron Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Acceleron Pharma Company Overview

Acceleron Pharma logo
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $178.75
Low: $178.75
High: $178.75

50 Day Range

MA: $176.25
Low: $172.08
High: $179.68

2 Week Range

Now: $178.75
Low: $108.82
High: $189.99

Volume

N/A

Average Volume

572,759 shs

Market Capitalization

$10.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.13